Drug Combination Details
| General Information of the Combination (ID: C95098) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | BIBR1532 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BIRC3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TERT | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFC | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G1 phase | ||||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-231 | Breast cancer | Homo sapiens | ||||
| Experimental
Result(s) |
Arsenic trioxide and BIBR1532 synergistically inhibit breast cancer cell proliferation through attenuation of NF-KappaB signaling pathway. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Arsenic trioxide and BIBR1532 synergistically inhibit breast cancer cell proliferation through attenuation of NF-KappaB signaling pathway. Life Sci. 2020 Sep 15;257:118060. | |||
